SBIR-STTR Award

New Assays for Expression Profiling of Micrornas
Award last edited on: 3/28/19

Sponsored Program
STTR
Awarding Agency
NIH : NHGRI
Total Award Amount
$224,951
Award Phase
1
Solicitation Topic Code
-----

Principal Investigator
Weijun Liu

Company Information

Nawgen LLC

4320 Forest Park Avenue Suite 303
Saint Louis, MO 63108
   (314) 485-9642
   info@nawgen.com
   www.nawgen.com

Research Institution

Washington University

Phase I

Contract Number: 1R41HG008247-01A1
Start Date: 4/1/15    Completed: 3/31/16
Phase I year
2015
Phase I Amount
$224,951
MicroRNAs (miRNAs) are involved in many diverse biological processes and a single miRNA can modulate the expression of hundreds of gene targets. Changes in miRNA expression could have profound biological impacts, leading to a variety of human diseases. To date, most miRNA expression profiling studies have relied on microarrays or high-throughput RNA sequencing (RNA-seq). For these high-throughput experiments, it is important to validate the profiling results with independent methods. Real-time PCR is considered as the gold standard for gene expression quantification and thus is ideal for validation of microarray or RNA-seq results. Furthermore, despite their wide use for miRNA profiling, there are some major limitations associated with microarrays and RNA-seq, such as the requirement of high-quality RNA samples. To address these issues, we have developed a new real-time RT-PCR method. With this new method, we have profiled the expression of cancer-related miRNAs in hundreds of archived tumor tissues, and identified novel miRNA signatures as predictive biomarkers for multiple types of cancer. Building on the success of our new method for cancer-related miRNA profiling, we propose to significantly expand the scope of the method by designing and testing new assays to encompass all known miRNAs in the human genome (Specific Aim 1). These miRNA assays will serve two main purposes: 1) As a reliable independent method for validation of high-throughput results from microarrays or RNA-seq; and 2) expression profiling of low- quality degraded RNA extracted from clinical tissues. In both cases, availability of these miRNA assays will enable researchers to correlate abnormal miRNA expression changes to human diseases by focusing on a selected set of miRNAs. To facilitate the selection of miRNA assays by end users, we also propose to establish an online database to present experimentally validated assays for all known human miRNAs (Specific Aim 2).

Public Health Relevance Statement:


Public Health Relevance:
MicroRNAs (miRNAs) are involved in many diverse biological processes and changes in miRNA expression lead to various human diseases. One major challenge in this field is the lack of assays for miRNA expression profiling analysis. To address this issue, we propose to develop new assay products to profile miRNA expression changes related to human diseases.

Project Terms:
Address; Algorithms; Archives; base; Bioinformatics; Biological; Biological Assay; Biological Markers; Biological Process; biological research; cancer type; Clinical; clinical application; Code; Data; Databases; design; Development; Formalin; Gene Expression; Gene Targeting; Genes; Goals; Gold; High-Throughput RNA Sequencing; Human; human disease; Human Genome; Individual; Lead; Malignant Neoplasms; Methods; MicroRNAs; Molecular Profiling; novel; Paraffin Embedding; Proteins; public health relevance; Publishing; Regulator Genes; Research; Research Infrastructure; Research Personnel; research study; Reverse Transcription; RNA; RNA Sequences; Sampling; Services; success; Testing; Time; Tissue Sample; Tissues; transcriptome sequencing; Tumor Tissue; Validation; Work

Phase II

Contract Number: ----------
Start Date: 00/00/00    Completed: 00/00/00
Phase II year
----
Phase II Amount
----